当前位置:首页 - 行情中心 - 启迪药业(000590) - 财务分析 - 利润表

启迪药业

(000590)

  

流通市值:26.55亿  总市值:26.56亿
流通股本:2.39亿   总股本:2.39亿

利润表

报告期2025-09-302025-06-302025-03-312024-12-31
公司类型通用通用通用通用
一、营业总收入224,815,751.88142,437,429.6165,220,251.47343,208,128.81
  营业收入224,815,751.88142,437,429.6165,220,251.47343,208,128.81
二、营业总成本250,688,000.98170,030,690.7681,374,066.11371,218,456.86
  营业成本119,899,263.3778,434,251.5734,274,422.07182,536,813.91
  税金及附加5,424,786.083,375,405.441,606,393.258,052,681.56
  销售费用45,418,416.2633,870,611.9517,241,678.3969,432,829.81
  管理费用66,053,068.6744,446,076.6424,150,788.6795,570,825.39
  研发费用11,663,083.028,292,249.343,367,126.5713,165,981.32
  财务费用2,229,383.581,612,095.82733,657.162,459,324.87
  其中:利息费用2,654,622.751,907,967.66899,884.163,661,916.25
  其中:利息收入476,514.79339,545.26181,997.231,271,591.37
三、其他经营收益
  加:公允价值变动收益----871,950.28
  加:投资收益92,339.1236,284.33161,696.82372,373.55
  资产处置收益3,537,636.013,444,349.77-118,765.884,780.83
  资产减值损失(新)-46,466.87-640.48--119,237,884.73
  信用减值损失(新)6,554,200.256,537,613.0827,813.76-26,901,757.6
  其他收益3,347,722.562,519,531.35967,625.235,964,521.81
四、营业利润-12,386,818.03-15,056,123.1-15,115,444.71-168,680,244.47
  加:营业外收入1,224,354.97200,501.2214,004.3148,374,373.54
  减:营业外支出1,573,697.11109,602.5491,557.831,832,674.27
五、利润总额-12,736,160.17-14,965,224.42-15,192,998.23-122,138,545.2
  减:所得税费用2,326,785.662,298,316.81,068,244.035,091,507.88
六、净利润-15,062,945.83-17,263,541.22-16,261,242.26-127,230,053.08
(一)按经营持续性分类
  持续经营净利润-15,062,945.83-17,263,541.22-16,261,242.26-127,230,053.08
(二)按所有权归属分类
  归属于母公司股东的净利润-14,820,604.47-17,170,056.39-16,256,161.33-125,471,522.88
  少数股东损益-242,341.36-93,484.83-5,080.93-1,758,530.2
  扣除非经常损益后的净利润-20,681,828.54-22,652,173.34-17,089,914.38-169,817,012.09
七、每股收益
  (一)基本每股收益-0.06-0.07-0.07-0.52
  (二)稀释每股收益-0.06-0.07-0.07-0.52
九、综合收益总额-15,062,945.83-17,263,541.22-16,261,242.26-127,230,053.08
  归属于母公司股东的综合收益总额-14,820,604.47-17,170,056.39-16,256,161.33-125,471,522.88
  归属于少数股东的综合收益总额-242,341.36-93,484.83-5,080.93-1,758,530.2
公告日期2025-10-302025-08-272025-04-282025-03-28
审计意见(境内)标准无保留意见
TOP↑